Venatorx Pharmaceuticals

61 articles about Venatorx Pharmaceuticals

• Venatorx Pharmaceuticals to Present Data at IDWeek 2021

  9/27/2021

  Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

• Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam

  8/17/2021

  Venatorx Pharmaceuticals today announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor (BL/BLI)

• Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

  7/28/2021

  Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

• Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

  6/29/2021

  Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.

• Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

  6/28/2021

  Venatorx Pharmaceuticals today announced that the first patient was dosed in a Phase 1 clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus (HBV) infection.

• Venatorx Pharmaceuticals to Present Preclinical Profile of its Hepatitis B Virus Clinical Candidate at the International Liver Congress 2021

  6/21/2021

  Venatorx Pharmaceuticals today announced that it will present at the International Liver CongressTM (ILC), the European Association for the Study of the Liver (EASL) annual meeting, which is scheduled to take place virtually June 23-26, 2021.

• Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

  3/10/2021

  VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021

• 

  Top 10 Pharm Country Companies to Receive NIH Funding in 2020

  3/3/2021

  Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.

• Venatorx Pharmaceuticals Names New Head of Regulatory Affairs

  1/28/2021

  Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx’s global regulatory strategy for its clinical and pre-clinical anti-infectives programs for Venatorx Pharmaceuticals

• Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

  11/24/2020

  Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (“CMC”).

• Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020

  10/21/2020

  Venatorx Pharmaceuticals today announced that it has two data presentations at IDWeek 2020, which is taking place virtually, starting today through October 25, 2020. The details of the presentations are as follows: Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-Beta-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy

  9/17/2020

  Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy. With over 25 years of biopharmaceutical industry experience, including multiple product and line extension launches, Mr. Sargent will be responsible for designing and executing Venatorx’s commercial strategy across its portfolio of clinical and preclinical antibacterial and antiviral programs.

• Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

  7/27/2020

  Venatorx Pharmaceuticals announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services to advance a novel series of Penicillin Binding Protein Inhibitors targeting multi-drug resistant Acinetobacter baumannii through Phase 1 clinical testing.

• Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row

  6/30/2020

  Venatorx Pharmaceuticals announced that it was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal.

• Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options

  4/29/2020

  Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam.

• Venatorx Pharmaceuticals Joins the Alliance for Biosecurity

  12/19/2019

  Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.

• CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

  11/25/2019

  CARB-X is awarding VenatoRx Pharmaceuticals, Inc. (Malvern, Pennsylvania, USA) up to US$4.1 million in non-dilutive funding, with the possibility of up to an additional US$8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.

• VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

  9/4/2019

  Dr. Larsen will help translate VenatoRx’s rich internal programs toward strategic public and private partnerships, and will help identify new growth opportunities for VenatoRx.

• VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

  8/29/2019

  VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).